A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study to Assess the Safety, Tolerability and Pharmacokinetics of DUR-928 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2016
At a glance
- Drugs DUR 928 (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; Pharmacokinetics
- 13 Sep 2016 Status changed from recruiting to completed.
- 04 Aug 2016 Status changed from not yet recruiting to recruiting.
- 12 Jul 2016 New trial record